Replies to post #322027 on NorthWest Biotherapeutics Inc (NWBO)

[eagle8]

Thanks Doc logic for sharing your thoughts.

Look at the 1st secondary objective again and you will realize that NWBO believes that SOC patients that were in captured chemo/rad pseudoprogressors that crossed over are doing well and that enough true progressors that crossed over are receiving salvage treatment benefit from L and or combo that it warrants comparison to other historical SOC/placebo. That is a big statement that goes right in line with research I found long ago about salvage therapy repotentiation created by use of DC therapy as well as the relationship of mesenchymal phenotype, created at progression by up to 85% of all tumors, being more susceptible to DC therapy. Putting this endpoint at the number 2 spot suggests a very high degree of confidence that these relationships exist to the point of statistical certainty. Best wishes.

I remember the first time we were talking on this board about reccuring tumors often mutated to mesenchymal type ( which is the most aggresive one) and giving the best response to DC-Vax.
One thing that was mentioned at that time ( flipper) was the low cytokines numbers ( if i am not mistaken). This was a reaction of the chemo/rad.
You mentioned that in Germany they found out that even this group reacted very good on DC-Vax. So that problem also solved.
All in all does this mean reccuring tumors (and than surgery) could mean
we could made stat sig for reccuring cancers versus historical SOC numbers?

I hope i understand this correct.

Thank you in advance for an answer.

Best to you ofcourse as a fellow long.